Ceftaroline

DEA Class; Rx

Common Brand Names; Teflaro

Indicated for treatment of community-acquired bacterial pneumonia (CABP)

Indicated for acute bacterial skin and skin structure infections (ABSSSI), including MRSA

Hypersensitivity to drug, excipients or other cephalosporins

• Diarrhea (5%)
• Nausea (4%)
• Rash (3%)
• Constipation (2%)
• Vomiting (2%)
• Increased transaminases (2%)
• Hypokalemia (2%)
• Phlebitis (2%)
• Blood and lymphatic system disorders: Anemia, eosinophilia, neutropenia, thrombocytopenia
• Cardiac disorders: Bradycardia, palpitations
• Gastrointestinal disorders: Abdominal pain
• General disorders and administration site conditions: Pyrexia
• Hepatobiliary disorders: Hepatitis
• Immune system disorders: Hypersensitivity, anaphylaxis
• Infections and infestations: Clostridium difficile colitis
• Metabolism and nutrition disorders: Hyperglycemia, hyperkalemia
• Nervous system disorders: Dizziness, convulsion
• Renal and urinary disorders: Renal failure
• Skin and subcutaneous tissue disorders: Urticaria

If anemia develops during or after treatment, consider drug-induced hemolytic anemia; perform diagnostic studies including a direct Coombs’ test; if drug-induced hemolytic anemia suspected, consider discontinuation; administer supportive care to patient (i.e. transfusion) if clinically indicated

Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria

Neurological adverse reactions reported during postmarketing surveillance in patients treated with cephalosporins; reactions include encephalopathy and seizures; most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment; if neurological adverse reactions occur, consider discontinuing therapy or making appropriate dosage adjustments in patients with renal impairment

No data in pregnant women are available

No data are available regarding presence in human milk, or the effects on breastfed infants or on milk production

1200 mg/day IV.

1200 mg/day IV.

weighing more than 33 kg: 1200 mg/day IV.
weighing 33 kg or less: 36 mg/kg/day IV.

2 years and older weighing more than 33 kg: 1200 mg/day IV.
2 years and older weighing 33 kg or less: 36 mg/kg/day IV.
younger than 2 years: 24 mg/kg/day IV.

2 to 11 months: 24 mg/kg/day IV.
1 month: 18 mg/kg/day IV.

Neonates at least 34 weeks gestational age and 12 days postnatal age: 18 mg/kg/day IV.
Neonates at least 34 weeks gestational age and younger than 12 days postnatal age: Safety and efficacy have not been established.
Neonates younger than 34 weeks gestational age: Safety and efficacy have not been established.